Affiliation:
1. From the Departments of Medical Oncology, Hospital Universitario La Fe; Hospital Universitari Doctor Peset, Valencia; Idibell-Institut Catalá d'Oncologia Duran i Reynals; Hospital de Sant Pau; Hospital Mutua de Terrassa; Hospital del Mar; Hospital Clinic i Provincial, Barcelona; Hospital General Universitario Gregorio Marañón; Hospital Universitario 12 de Octubre, Madrid; Hospital Clínico Universitario Lozano Blesa, Zaragoza; Hospital Universitari Germans Trias i Pujol, Badalona; Hospital Universitari...
Abstract
Purpose To assess the efficacy of a risk-adapted treatment policy for patients with stage I seminoma by using universally accepted risk criteria. Patients and Methods Between 1999 and 2003, 314 patients with clinical stage I seminoma after orchiectomy were prospectively included. One hundred patients (31.8%) presented no risk factors and were managed with surveillance. In contrast, 131 patients (41.7%) had tumors larger than 4 cm, 33 patients (10.5%) had rete testis involvement, and 50 patients (15.9%) had both risk factors. All the latter received two courses of adjuvant carboplatin. Results Chemotherapy was well tolerated, as only 17 patients (7.9%) presented grade 3 to 4 toxicity. Relapses were observed in six patients (6.0%) on surveillance and in seven patients (3.3%) treated with carboplatin (0.8% of tumors larger than 4 cm, 9.1% of those involving the rete testis, and 6.0% of patients with both risk criteria). All were located at the retroperitoneum, except for one at the spermatic cord. Median tumor size was 25 mm (range, 11 to 70 mm), and median time to relapse was 9 months (range, 4 to 28 months). All patients were rendered disease-free with chemotherapy (etoposide plus cisplatin). Median follow-up was 34 months (range, 12 to 72 months). The actuarial 5-year disease-free survival rate was 93.4% for patients on surveillance and 96.2% for patients treated with adjuvant chemotherapy. Overall 5-year survival was 100%. Conclusion Adjuvant carboplatin is effective in reducing the relapse rate in patients with stage I seminoma and risk factors. A risk-adapted strategy is safe and feasible and should be considered an alternative to systematic approaches, such as irradiation, chemotherapy, or surveillance.
Publisher
American Society of Clinical Oncology (ASCO)
Reference24 articles.
1. Treatment of clinical stage I germ cell tumors
2. Zagars GK: Management of stage I seminoma: Radiotherapy, in Horwich A (ed): Testicular Cancer: Investigation and Management (ed 2). London, United Kingdom, Chapman & Hall, pp 99,1996-121
3. Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis
4. THE MANAGEMENT OF STAGE I TESTIS CANCER
5. Oliver RT, Mason M, Von der Masse H, et al: A randomised comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis, following orchidectomy: MRC TE 19/EORTC 30982. Proc Am Soc Clin Oncol 23:385,2004, (abstr 4517)
Cited by
192 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献